6-K 1 gff6k_122415.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

December 23, 2015

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

 

 

Novo Nordisk A/S – Share repurchase programme  

 

 

Bagsværd, Denmark, 23 December 2015 – On 29 October 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.

 

Under the programme initiated 29 October 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 4.5 billion in the period from 29 October 2015 to 1 February 2016.

 

Since the announcement as of 14 December 2015, the following transactions have been made under the programme: 

 

 

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement 6,349,000   2,414,688,946
14 December 2015 215,000 377.70 81,205,457
15 December 2015 170,000 380.72 64,721,873
16 December 2015 195,000 387.08 75,481,283
17 December 2015 190,000 391.27 74,342,174
18 December 2015 180,000 388.92 70,005,438
21 December 2015 180,000 392.52 70,652,898
22 December 2015 200,000 386.46 77,292,640
Accumulated under the programme 7,679,000   2,928,390,709

 

 

With the transactions stated above, Novo Nordisk owns a total of 52,168,703 B shares of DKK 0.20, corresponding to 2.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a 12-month period beginning 30 January 2015. As of 22 December 2015, Novo Nordisk has repurchased a total of 43,582,251 B shares equal to a transaction value of DKK 15,928,390,199.

 

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

 

Further information 

Media:    
Nina Weimann +45 3075 4041 niwm@novonordisk.com  
     

Investors:

   
Peter Hugreffe Ankersen +45 3075 9085   phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje +45 3079 8519 kpvj@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

 

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

    Company announcement No 80 / 2015

 

 


 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: December 24, 2015

 

NOVO NORDISK A/S

 

Lars Rebien Sørensen,

Chief Executive Officer